Paper29540327
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Avila MS and 20 others. J Am Coll Cardiol, 2018. Cited by 415 papers, by iCite.
Cite this record
ConductScience Library. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. Papers, record 29540327. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29540327
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenergic beta-Antagonists | Major topic |
| Antineoplastic Agents | Major topic |
| Cardiotoxicity | Major topic |
| Carvedilol | Major topic |
| Adult | |
| Breast Neoplasms | |
| Double-Blind Method | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Middle Aged | |
| Prospective Studies |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01724450 | Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT06005259 | Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX) | Background | ClinicalTrials.gov |
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 29773156 | Beta-Blockers for Primary Prevention of Anthracycline Cardiotoxicity: Not Quite Ready for Prime Time. | https://conductscience.org/library/papers/29773156 | PubMed |
| Comment in | 30165996 | Can Carvedilol Prevent Chemotherapy-Related Cardiotoxicity?: A Dream to Be Balanced With Tolerability. | https://conductscience.org/library/papers/30165996 | PubMed |
| Comment in | 30165997 | Reply: Can Carvedilol Prevent Chemotherapy-Related Cardiotoxicity?: A Dream to Be Balanced With Tolerability. | https://conductscience.org/library/papers/30165997 | PubMed |
Cited by297
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 415 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958440 | Pharmacologic prevention of cardiotoxicity in breast cancer: a Bayesian network meta-analysis and meta-regression. | Cardiooncology | 2026 | https://conductscience.org/library/papers/42958440 | PubMed |
| 42938878 | Cardiovascular Magnetic Resonance for Early Detection of Cancer Therapy-Related Cardiac Dysfunction: From Multiparametric Tissue Signatures to Clinical Pathways. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938878 | PubMed |
| 42920518 | Efficacy of beta-blockers in preventing cardiotoxicity in breast cancer patients receiving anthracyclines: a GRADE-assessed systematic review and meta-analysis with trial sequential analysis. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42920518 | PubMed |
| 42836855 | Dapagliflozin for attenuating early anthracycline-associated cardiac changes (DAPA-AIC): a randomized, double-blind, placebo-controlled trial. | Future Sci OA | 2026 | https://conductscience.org/library/papers/42836855 | PubMed |
| 42739599 | Cardio-Oncology in Older Adults: Evidence Gaps, Geriatric Considerations, and Future Directions. | J Clin Med | 2026 | https://conductscience.org/library/papers/42739599 | PubMed |
| 42614945 | Beyond β-Adrenergic Receptor Brake: Compartment-Selective GRK2 Programs from Heart Failure to Cardio-Oncology. | Kinases Phosphatases | 2026 | https://conductscience.org/library/papers/42614945 | PubMed |
| 42554547 | Immune Pathways in Doxorubicin Cardiotoxicity: A Cardio-Immunology Perspective: JACC CardioOncology State-of-the-Art Review. | JACC CardioOncol | 2026 | https://conductscience.org/library/papers/42554547 | PubMed |
| 42505901 | Sacubitril/Valsartan for Prevention of Cancer Therapy-Related Cardiac Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | J Cardiovasc Dev Dis | 2026 | https://conductscience.org/library/papers/42505901 | PubMed |
| 42455418 | Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists. | Cardiovasc Toxicol | 2026 | https://conductscience.org/library/papers/42455418 | PubMed |
| 42384221 | From Cardioprotection to Trial Design: Rethinking Cardiac Safety in Oncology. | Curr Heart Fail Rep | 2026 | https://conductscience.org/library/papers/42384221 | PubMed |
| 42356463 | Carvedilol Exerts Cardioprotective Effects Against Doxorubicin Toxicity via Autophagy Modulation and Energetics Restoration. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42356463 | PubMed |
| 42253929 | Short-Term, Cycle-Synchronized Adjunctive Therapy With Crocus Total Glucosides Tablets for Cardiac Protection Against Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42253929 | PubMed |
| 42181413 | Sodium-Glucose Cotransporter-2 Inhibitors in Anthracycline-Treated Cancer Patients: A Narrative Review of Emerging Cardioprotective Evidence. | Cureus | 2026 | https://conductscience.org/library/papers/42181413 | PubMed |
| 42104505 | Clinical utility of the HFA-ICOS risk tool in real-world HER2-positive breast cancer patients receiving therapy. | Cardiooncology | 2026 | https://conductscience.org/library/papers/42104505 | PubMed |
| 42057201 | Cardiovascular care in adult cancer survivorship post-therapy: a cross-sectional analysis of clinical practice guidelines. | Cardiooncology | 2026 | https://conductscience.org/library/papers/42057201 | PubMed |
| 42045526 | A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/42045526 | PubMed |
| 41993860 | Protective effects of beta-blockers against anthracycline- and trastuzumab-related cardiotoxicity: a systematic review based on conventional and Bayesian network meta-analysis. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/41993860 | PubMed |
| 41977162 | Cardiotoxicity of Antitumor Agents: Therapeutic Challenges in Heart Failure with Reduced and Preserved Ejection Fraction. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977162 | PubMed |
| 41975552 | Review on cardioprotective strategies in the setting of chemotherapy-induced cardiotoxicity. | Cardiooncology | 2026 | https://conductscience.org/library/papers/41975552 | PubMed |
| 41971817 | Discovery of Zidovudine as a cardiomyocyte protectant for doxorubicin-induced toxicity through high-throughput phenotypic drug screening. | Fundam Res | 2026 | https://conductscience.org/library/papers/41971817 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| CARVEDILOL | CHEMBL723 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL723 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29540327
GET https://conductscience.org/api/papers/v1/29540327/authors?page=2